EP547
Cholestatic Pruritus
Phase 2Active
Key Facts
About Escient Pharmaceuticals
Escient Pharmaceuticals is a San Diego-based biotech pioneering the development of oral MRGPR antagonists to treat neurosensory-inflammatory disorders. Its lead clinical candidates are EP262, an MRGPRX2 antagonist for mast cell-mediated diseases like chronic urticaria, and EP547, an MRGPRX4 antagonist for cholestatic pruritus. Founded in 2017, the company was acquired by Incyte in May 2024, providing significant resources to advance its novel pipeline. Escient's approach targets the interface between the neurosensory and immune systems, aiming to create differentiated treatments for underserved patient populations.
View full company profileTherapeutic Areas
Other Cholestatic Pruritus Drugs
| Drug | Company | Phase |
|---|---|---|
| Cholestatic Pruritus Trial | Science 37 | Phase 2 |